Evidence map›Paper›PMID 28682658›Full record

ArticleJournal of women's health (2002)2017

Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Women Without HIV.

Andrew Edmonds, Christina Ludema, Joseph J Eron, Stephen R Cole, Adebola A Adedimeji, Mardge H Cohen, Hannah L Cooper, Margaret Fischl, Mallory O Johnson, Denise D Krause and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of women's health (2002), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Health Insurance and the Promise of Incrementalism.Journal of women's health (2002) · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Andrew Edmonds1 Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
Christina Ludema2 Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
Joseph J Eron2 Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
Stephen R Cole1 Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
Adebola A Adedimeji3 Department of Epidemiology and Population Health, Albert Einstein College of Medicine , Bronx, New York.
Mardge H Cohen4 Department of Medicine, Cook County Health and Hospital System and Rush University , Chicago, Illinois.
Hannah L Cooper5 Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University , Atlanta, Georgia .
Margaret Fischl6 Division of Infectious Diseases, Department of Medicine, University of Miami School of Medicine , Miami, Florida.
Mallory O Johnson7 Department of Medicine, University of California , San Francisco, San Francisco, California.
Denise D Krause8 Department of Biomedical Materials Science, School of Dentistry, University of Mississippi Medical Center , Jackson, Mississippi.
Dan Merenstein9 Department of Family Medicine, Georgetown University Medical Center , Washington, District of Columbia.
Joel Milam10 Department of Preventive Medicine, Keck School of Medicine, University of Southern California , Los Angeles, California.
Tracey E Wilson11 Department of Community Health Sciences, School of Public Health, State University of New York (SUNY) Downstate Medical Center , Brooklyn, New York.
Adaora A Adimora1 Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
University of North Carolina at Chapel Hill · USAlbert Einstein College of Medicine · USEmory University · USGeorgetown University Medical Center · USRush University · USUniversity of California, San Francisco · USUniversity of Miami · USUniversity of Mississippi Medical Center · USUniversity of Southern California · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
UNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000454NHLBI NIH HHS U01 HL146194NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI050410NIAID NIH HHS R38 AI140299NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01 AI103408NIA NIH HHS U54 AG062334NICHD NIH HHS U01 HD032632NIDA NIH HHS K24 DA037034
6 · The paper itself

Abstract

backgroundAmong low-income women with and without HIV, it is a priority to reduce age-related comorbidities, including hypertension and its sequelae. Because consistent health insurance access has been identified as an important factor in controlling many chronic diseases, we estimated the effects of coverage interruption on loss of hypertension control in a cohort of women in the United States.

methodsWe analyzed prospective, longitudinal data from the Women's Interagency HIV Study. HIV-infected and HIV-uninfected women were included between 2005 and 2014 when they reported health insurance at consecutive biannual visits and had controlled hypertension, and were followed for any insurance break and loss of hypertension control. We estimated hazard ratios (HRs) by Cox proportional hazards regression with inverse-probability-of-treatment-and censoring weights (marginal structural models), and plotted the cumulative incidence of hypertension control loss.

resultsAmong 890 HIV-infected women, the weighted HR for hypertension control loss comparing health insurance interruption to uninterrupted coverage was 1.37 (95% confidence interval [CI], 0.99-1.91). Inclusion of AIDS Drug Assistance Program (ADAP) participation with health insurance modestly increased the HR (1.47; 95% CI, 1.04-2.07). Analysis of 272 HIV-uninfected women yielded a similar HR (1.39; 95% CI, 0.88-2.21). Additionally, there were indications of uninterrupted coverage having a protective effect on hypertension when compared with the natural course in HIV-infected (HR, 0.82; 95% CI, 0.61-1.11) and HIV-uninfected (HR, 0.78; 95% CI, 0.52-1.19) women.

conclusionsThis study provides evidence that health insurance continuity promotes hypertension control in key populations. Interventions that ensure coverage stability and ADAP access should be a policy priority.

Indexed as

Insurance, HealthAdultAnti-HIV AgentsAntihypertensive AgentsBlood PressureFemaleHealth Services AccessibilityHIV InfectionsHumansHypertensionIncidenceInsurance CoverageLongitudinal StudiesMedicaidMedically UninsuredMiddle AgedAnti-HIV AgentsAntihypertensive Agentshealth insuranceHIV/AIDShypertensionwomen

Identifiers

PMID28682658
PMCPMC5733655
OpenAlexW2727452692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.